glp 1 increase pregnancy Taking GLP-1s during the first trimester of does not appear to substantially the risk of adverse outcomes GLP1-RAs: The New Era of

113 SenguptaR.HolmgrenA

TB-500 Inside the GLOW Protocol Inside GLOW, TB-500 acts as the logistics coordinator

NICE guidance (NG28) recommends GLP-1 receptor agonists as a treatment option for adults with type 2 diabetes when: Triple therapy with metformin and two other oral drugs is not effective, not tolerated or contraindicated The person has a BMI of 35 kg/m or higher (adjust accordingly for people from particular ethnic groups) and specific psychological or other medical problems associated with obesity The person has a BMI lower than 35 kg/m and insulin would have significant occupational implications, or weight loss would benefit other significant obesity-related comorbidities GLP-1 receptor agonists may also be considered in combination with insulin therapy in specialist care settings Beyond glycaemic control, specific GLP-1 receptor agonists offer significant cardiovascular benefits

Stick to the recommended serving size for the best long-term value